We are proud to announce that we have acquired E Ink’s digital microfluidics unit to form our US subsidiary. Combining the technologies of the two companies will enable the delivery of a revolutionary desktop protein and gene “bioprinter” with breakthrough speed and convenience for researchers in human health, agriculture, and other markets of global importance. Nuclera has been working in a strategic partnership with E Ink since 2018 to deploy Nuclera’s proprietary biopolymer synthesis technologies on E Ink’s digital microfluidic devices. Instead of the physical channels found in conventional microfluidics, digital microfluidics uses electronic signals to guide microdroplets. When combined with Nuclera biopolymer synthesis, this advanced lab-on-a-chip technology will enable a user to digitally program the next day bioprinting of proteins and genes on a desktop device. The result is a bioprinter that gives unprecedented access to biology. Commercialization is expected in 2022. Read More